Mismatch between clinically defined classification of ALS stage and the burden of cerebral pathology.
Amyotrophic lateral sclerosis
Clinical classification
Early stage
Longitudinal analysis
Magnetic resonance imaging
Texture analysis
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
28 Jan 2024
28 Jan 2024
Historique:
received:
16
11
2023
accepted:
10
01
2024
revised:
05
01
2024
medline:
29
1
2024
pubmed:
29
1
2024
entrez:
28
1
2024
Statut:
aheadofprint
Résumé
This study aimed to investigate the clinical stratification of amyotrophic lateral sclerosis (ALS) patients in relation to in vivo cerebral degeneration. One hundred forty-nine ALS patients and one hundred forty-four healthy controls (HCs) were recruited from the Canadian ALS Neuroimaging Consortium (CALSNIC). Texture analysis was performed on T1-weighted scans to extract the texture feature "autocorrelation" (autoc), an imaging biomarker of cerebral degeneration. Patients were stratified at baseline into early and advanced disease stages based on criteria adapted from ALS clinical trials and the King's College staging system, as well as into slow and fast progressors (disease progression rates, DPR). Patients had increased autoc in the internal capsule. These changes extended beyond the internal capsule in early-stage patients (clinical trial-based criteria), fast progressors, and in advanced-stage patients (King's staging criteria). Longitudinal increases in autoc were observed in the postcentral gyrus, corticospinal tract, posterior cingulate cortex, and putamen; whereas decreases were observed in corpus callosum, caudate, central opercular cortex, and frontotemporal areas. Both longitudinal increases and decreases of autoc were observed in non-overlapping regions within insula and precentral gyrus. Within-criteria comparisons of autoc revealed more pronounced changes at baseline and longitudinally in early- (clinical trial-based criteria) and advanced-stage (King's staging criteria) patients and fast progressors. In summary, comparative patterns of baseline and longitudinal progression in cerebral degeneration are dependent on sub-group selection criteria, with clinical trial-based stratification insufficiently characterizing disease stage based on pathological cerebral burden.
Identifiants
pubmed: 38282082
doi: 10.1007/s00415-024-12190-x
pii: 10.1007/s00415-024-12190-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Pupillo E et al (2014) Long-term survival in amyotrophic lateral sclerosis: a population-based study. Ann Neurol 75(2):287–297
pubmed: 24382602
doi: 10.1002/ana.24096
Hardiman O et al (2017) Amyotrophic lateral sclerosis. Nat Rev Dis Prim 3(1):1–19
Menke RAL et al (2014) Widespread grey matter pathology dominates the longitudinal cerebral MRI and clinical landscape of amyotrophic lateral sclerosis. Brain 137(Pt 9):2546–2555
pubmed: 24951638
pmcid: 4132644
doi: 10.1093/brain/awu162
Agosta F et al (2012) The cortical signature of amyotrophic lateral sclerosis. PLoS One 7(8):1–8
doi: 10.1371/journal.pone.0042816
D’Ambrosio A et al (2014) Frontotemporal cortical thinning in amyotrophic lateral sclerosis. Am J Neuroradiol 35(2):304–310
pubmed: 24113470
pmcid: 7965753
doi: 10.3174/ajnr.A3753
Cirillo M et al (2012) Widespread microstructural white matter involvement in amyotrophic lateral sclerosis: a whole-brain DTI study. AJNR Am J Neuroradiol 33(6):1102–1108
pubmed: 22300932
pmcid: 8013257
doi: 10.3174/ajnr.A2918
Kasper E et al (2014) Microstructural White matter changes underlying cognitive and behavioural impairment in ALS—an in vivo study using DTI. PLoS One 9(12):e114543
pubmed: 25501028
pmcid: 4263750
doi: 10.1371/journal.pone.0114543
Floeter MK, Bageac D, Danielian LE, Braun LE, Traynor BJ, Kwan JY (2016) Longitudinal imaging in C9orf72 mutation carriers: relationship to phenotype. NeuroImage Clin 12:1035–1043
pubmed: 27995069
pmcid: 5153604
doi: 10.1016/j.nicl.2016.10.014
Van Der Graaff MM et al (2011) Upper and extra-motoneuron involvement in early motoneuron disease: a diffusion tensor imaging study. Brain 134(4):1211–1228
pubmed: 21362631
doi: 10.1093/brain/awr016
Floeter MK, Danielian LE, Braun LE, Wu T (2018) Longitudinal diffusion imaging across the C9orf72 clinical spectrum. J Neurol Neurosurg Psychiatry 89(1):53–60
pubmed: 29054917
doi: 10.1136/jnnp-2017-316799
Schuster C et al (2014) Cortical thinning and its relation to cognition in amyotrophic lateral sclerosis. Neurobiol Aging 35(1):240–246
pubmed: 23992619
doi: 10.1016/j.neurobiolaging.2013.07.020
Walhout R et al (2015) Cortical thickness in ALS: towards a marker for upper motor neuron involvement. J Neurol Neurosurg Psychiatry 86(3):288–294
pubmed: 25121571
doi: 10.1136/jnnp-2013-306839
Kassubek J et al (2018) Imaging the pathoanatomy of amyotrophic lateral sclerosis in vivo: targeting a propagation-based biological marker. J Neurol Neurosurg Psychiatry 89(4):374–381
pubmed: 29101254
doi: 10.1136/jnnp-2017-316365
Meier JM et al (2020) Connectome-based propagation model in amyotrophic lateral sclerosis. Ann Neurol 87(5):725–738
pubmed: 32072667
pmcid: 7186838
doi: 10.1002/ana.25706
Querin G et al (2019) Presymptomatic spinal cord pathology in c9orf72 mutation carriers: a longitudinal neuroimaging study. Ann Neurol 86(2):158–167
pubmed: 31177556
doi: 10.1002/ana.25520
Kassner A, Thornhill RE (2010) Texture analysis: a review of neurologic MR imaging applications. Am J Neuroradiol 31(5):809–816
pubmed: 20395383
pmcid: 7964174
doi: 10.3174/ajnr.A2061
Haralick RM, Dinstein I, Shanmugam K (1973) Textural features for image classification. IEEE Trans Syst Man Cybern 3(6):610–621
doi: 10.1109/TSMC.1973.4309314
Maani R, Yang YH, Kalra S (2015) Voxel-based texture analysis of the brain. PLoS One 10(3):e0117759
pubmed: 25756621
pmcid: 4355627
doi: 10.1371/journal.pone.0117759
Ishaque A et al (2018) Texture analysis to detect cerebral degeneration in amyotrophic lateral sclerosis. Can J Neurol Sci 45(5):533–539
pubmed: 30234470
doi: 10.1017/cjn.2018.267
Ishaque A et al (2019) Corticospinal tract degeneration in ALS unmasked in T1-weighted images using texture analysis. Hum Brain Mapp 40(4):1174–1183
pubmed: 30367724
doi: 10.1002/hbm.24437
Ishaque A et al (2022) Distinct patterns of progressive gray and white matter degeneration in amyotrophic lateral sclerosis. Hum Brain Mapp 43(5):1519–1534
pubmed: 34908212
doi: 10.1002/hbm.25738
Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases (2000) “El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis”, Amyotroph. Lateral Scler Other Motor Neuron Disord 1(5):293–9
doi: 10.1080/146608200300079536
Cedarbaum JM et al (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci 169(1–2):13–21
pubmed: 10540002
doi: 10.1016/S0022-510X(99)00210-5
Roche JC et al (2012) A proposed staging system for amyotrophic lateral sclerosis. Brain 135(3):847–852
pubmed: 22271664
pmcid: 3286327
doi: 10.1093/brain/awr351
Balendra R et al (2014) Estimating clinical stage of amyotrophic lateral sclerosis from the ALS functional rating scale. Amyotroph Lateral Scler Front Degener 15(3–4):279–284
doi: 10.3109/21678421.2014.897357
Abrahams S, Newton J, Niven E, Foley J, Bak TH (2014) Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Front Degener 15(1–2):9–14
doi: 10.3109/21678421.2013.805784
Bensimon G, Lacomblez L, Meininger V (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 330(9):585–591
pubmed: 8302340
doi: 10.1056/NEJM199403033300901
Abe K et al (2017) Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16(7):505–512
doi: 10.1016/S1474-4422(17)30115-1
Ta D et al (2021) Progressive neurochemical abnormalities in cognitive and motor subgroups of amyotrophic lateral sclerosis. Neurology 97(8):e803
pubmed: 34426551
pmcid: 8397589
doi: 10.1212/WNL.0000000000012367
Fang T et al (2017) Comparison of the King’s and MiToS staging systems for ALS. Amyotroph Lateral Scler Frontotemporal Degener 18(3–4):227
pubmed: 28054828
pmcid: 5425622
doi: 10.1080/21678421.2016.1265565
Kalra S et al (2020) The Canadian ALS Neuroimaging Consortium (CALSNIC)-a multicentre platform for standardized imaging and clinical studies in ALS. medRxiv. https://doi.org/10.1101/2020.07.10.20142679
doi: 10.1101/2020.07.10.20142679
Gaser C, Dahnke R (2016) CAT-A computational anatomy toolbox for the analysis of structural MRI data. biorxiv. https://doi.org/10.1101/2022.06.11.495736
doi: 10.1101/2022.06.11.495736
Ashburner J (2007) A fast diffeomorphic image registration algorithm. Neuroimage 38(1):95–113
pubmed: 17761438
doi: 10.1016/j.neuroimage.2007.07.007
Fortin JP et al (2017) Harmonization of multi-site diffusion tensor imaging data. Neuroimage 161:149–170
pubmed: 28826946
doi: 10.1016/j.neuroimage.2017.08.047
Johnson WE, Li C, Rabinovic A (2007) Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8(1):118–127
pubmed: 16632515
doi: 10.1093/biostatistics/kxj037
Tahedl M et al (2023) Brainstem–cortex disconnection in amyotrophic lateral sclerosis: bulbar impairment, genotype associations, asymptomatic changes and biomarker opportunities. J Neurol 270(7):3511–3526
pubmed: 37022479
pmcid: 10267265
doi: 10.1007/s00415-023-11682-6
Hughes JT (1982) Pathology of amyotrophic lateral sclerosis. Adv Neurol 36:61–74
pubmed: 7180695
Turner MR, Agosta F, Bede P, Govind V, Lulé D, Verstraete E (2012) Neuroimaging in amyotrophic lateral sclerosis. Biomark Med 6(3):319–337
pubmed: 22731907
doi: 10.2217/bmm.12.26
Uddin LQ, Nomi JS, Hébert-Seropian B, Ghaziri J, Boucher O (2017) Structure and function of the human insula. J Clin Neurophysiol. https://doi.org/10.1097/WNP.0000000000000377
doi: 10.1097/WNP.0000000000000377
pubmed: 28644199
pmcid: 6032992
Johnson BS, Snead D, Lee JJ, McCaffery JM, Shorter J, Gitler AD (2009) TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem 284(30):20329–20339
pubmed: 19465477
pmcid: 2740458
doi: 10.1074/jbc.M109.010264
Jucker M, Walker LC (2013) Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501(7465):45–51
pubmed: 24005412
pmcid: 3963807
doi: 10.1038/nature12481
Verstraete E, Veldink JH, Hendrikse J, Schelhaas HJ, Van Den Heuvel MP, Van Den Berg LH (2012) Structural MRI reveals cortical thinning in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 83(4):383–388
pubmed: 21965521
doi: 10.1136/jnnp-2011-300909
Bede P, Hardiman O (2018) Longitudinal structural changes in ALS: a three time-point imaging study of white and gray matter degeneration. Amyotroph Lateral Scler Frontotemporal Degener 19(3–4):232–241
pubmed: 29214883
doi: 10.1080/21678421.2017.1407795
Zhenfei L, Shiru D, Xiaomeng Z, Cuifang C, Yaling L (2019) Discontiguous or contiguous spread patterns affect the functional staging in patients with sporadic amyotrophic lateral sclerosis. Front Neurol. https://doi.org/10.3389/fneur.2019.00523
doi: 10.3389/fneur.2019.00523
pubmed: 31191429
pmcid: 6540586
Cardenas AM et al (2017) Pathology of callosal damage in ALS: an ex-vivo, 7 T diffusion tensor MRI study. NeuroImage Clin 15:200–208
pubmed: 28529876
pmcid: 5429246
doi: 10.1016/j.nicl.2017.04.024
Sugiyama M et al (2013) Increased number of astrocytes and macrophages/microglial cells in the corpus callosum in amyotrophic lateral sclerosis. Neuropathology 33(6):591–599
pubmed: 23530811
doi: 10.1111/neup.12027
Braak H, Del Tredici K (2018) Anterior cingulate cortex TDP-43 pathology in sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 77(1):74–83
pubmed: 29186496
doi: 10.1093/jnen/nlx104
Lawyer T, Netsky MG (1953) Amyotrophic lateral sclerosis. AMA Arch Neurol Psychiatry 69(2):171–192
pubmed: 13007227
doi: 10.1001/archneurpsyc.1953.02320260029002
Brettschneider J et al (2013) Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 74(1):20–38
pubmed: 23686809
pmcid: 3785076
doi: 10.1002/ana.23937
Kamo H, Haebara H, Akiguchi I, Kameyama M, Kimura H, McGeer PL (1987) A distinctive distribution of reactive astroglia in the precentral cortex in amyotrophic lateral sclerosis. Acta Neuropathol 74(1):33–38
pubmed: 3310502
doi: 10.1007/BF00688335
Murayama S, Inoue K, Kawakami H, Bouldin TW, Suzuki K (1991) A unique pattern of astrocytosis in the primary motor area in amyotrophic lateral sclerosis. Acta Neuropathol 82(6):456–461
pubmed: 1785258
doi: 10.1007/BF00293379
Sharma KR, Sheriff S, Maudsley A, Govind V (2013) Diffusion tensor imaging of basal ganglia and thalamus in amyotrophic lateral sclerosis. J Neuroimaging 23(3):368–374
pubmed: 22273090
doi: 10.1111/j.1552-6569.2011.00679.x
Ta D et al (2020) Reliability of 3D texture analysis: a multicenter MRI study of the brain. J Magn Reson Imaging 51(4):1200–1209
pubmed: 31423714
doi: 10.1002/jmri.26904
Verstraete E, Turner MR, Grosskreutz J, Filippi M, Benatar M (2015) Mind the gap: the mismatch between clinical and imaging metrics in ALS. Amyotroph Lateral Scler Front Degener 16(7–8):524–529
doi: 10.3109/21678421.2015.1051989
Qureshi M, Schoenfeld DA, Paliwal Y, Shui A, Cudkowicz ME (2009) The natural history of ALS is changing: improved survival. Amyotroph Lateral Scler 10(5–6):324–331
pubmed: 19922119
doi: 10.3109/17482960903009054
Miller TM et al (2022) Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med 387(12):1099–1110
pubmed: 36129998
doi: 10.1056/NEJMoa2204705
Sun Q et al (2020) CSF neurofilament light chain elevation predicts ALS severity and progression. Front Neurol. https://doi.org/10.3389/fneur.2020.00919
doi: 10.3389/fneur.2020.00919
pubmed: 33613424
pmcid: 7802749
Tahedl M et al (2022) Propagation patterns in motor neuron diseases: Individual and phenotype-associated disease-burden trajectories across the UMN-LMN spectrum of MNDs. Neurobiol Aging 109:78–87
pubmed: 34656922
doi: 10.1016/j.neurobiolaging.2021.04.031